The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity

COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus. However, boosting innate responses may represent an innovative way to immediately fight future emerging viral infections or boost vaccines. MV130 is a mucosal immunotherapy, based on a mixture of whole heat-inact...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Carlos del Fresno, Juan García-Arriaza, Sarai Martínez-Cano, Ignacio Heras-Murillo, Aitor Jarit-Cabanillas, Joaquín Amores-Iniesta, Paola Brandi, Gillian Dunphy, Carmen Suay-Corredera, Maria Rosaria Pricolo, Natalia Vicente, Andrés López-Perrote, Sofía Cabezudo, Ana González-Corpas, Oscar Llorca, Jorge Alegre-Cebollada, Urtzi Garaigorta, Pablo Gastaminza, Mariano Esteban, David Sancho
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	innate immunity viral infections polybacterial mucosal immunotherapy SARS-CoV-2 vaccine immunogenicity Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/af5d6f5a1ddb4342b33ea0dcb74a03d1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity

Ejemplares similares